Thursday, May 24, 2012
Insmed Inc., of Monmouth Junction, N.J., began screening patients for TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial), its U.S. Phase II trial of Arikace (liposomal amikacin for inhalation) in nontuberculous mycobacterial lung disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.